DOCSLIB.ORG

Enpp1 and Osteoblasts

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Enpp1 and Osteoblasts Nucleotides as regulators of bone cell function and mineralisation Mark Omar Raimes Hajjawi A thesis submitted for the fulfilment of the degree of Doctor of Philosophy Department of Cell and Developmental Biology University College London 2014 Declaration of authorship Declaration of authorship I, Mark Omar Raimes Hajjawi, declare that this thesis titled ‘Nucleotides as regulators of bone cell function and mineralisation’ and the work presented in it are my own. I confirm that: This work was done wholly while in candidature for a research degree at this university. No part of this thesis has previously been submitted for a degree or any other qualification at this university or any other institution. Where I have consulted the published work of others, this is always clearly attributed. Where I have quoted from the work of others, the source is always given. With the exception of such quotations, this thesis is entirely my own work. I have acknowledged all main sources of help. Where the thesis is based on work done by myself jointly with others, I have made clear exactly what was done by others and what I have contributed myself. Signed: _________________________________________________ Date: ___________________________________________________ 2 Abstract Abstract Most cells, including bone cells, release ATP into the extracellular environment. A considerable body of previous work has shown that ATP, acting through the P2 receptors, inhibits bone formation by osteoblasts and increases bone resorption by osteoclasts. This work focuses on the action of two key breakdown products of ATP, pyrophosphate and adenosine on bone cell function. Pyrophosphate, a ubiquitous physicochemical inhibitor of mineralisation, is formed from extracellular ATP by the action of ecto-nucleotide pyrophosphatase phosphodiesterases (NPPs); in bone these enzymes act in opposition to alkaline phosphatase. Adenosine, which can be generated in a number of ways from ATP, has been previously reported to stimulate both osteoblast and osteoclast function. However, using in vitro cultures, I found that it had little or no effect on the differentiation and bone forming capacity of rat osteoblasts, nor on the formation and resorptive function of mouse osteoclasts. I investigated the possibility that osteocytes, which form an interconnected cellular network within bone, might regulate mineralisation via NPPs. I found that cultured, primary osteocyte-like cells derived from mouse bone expressed Enpp1 mRNA. Osteocyte lacunae in the femora of Enpp1-/- mice imaged by scanning electron microscopy were found to be reduced in area by about 35%; indirect estimates of lacunar size using microCT imaging were in agreement. These results are consistent with the notion that ATP-derived pyrophosphate is important for maintenance of osteocyte lacunae size. Enpp1-/- mouse bones (humerus) were found to have reduced cortical bone diameter, reduced cortical porosity and an increased endosteal diameter compared to wild types, suggesting that the knockout phenotype also involves increased bone resorption and decreased bone formation. Histology and microCT of Enpp1-/- mice confirmed inappropriate joint mineralisation and showed that cartilage in the trachea and ear pinna was also mineralised, as were whisker sheaths. Osteoblasts, osteoclasts and osteocytes cultured in vitro from Enpp1-/- mice were found to release less ATP compared to cells from Enpp1+/+ mice in static conditions and after fluid flow stimulation. Enpp1- /- osteoblasts and osteoclasts also contained higher levels of intracellular ATP. Enpp1-/-osteoblasts showed increased bone production in vitro compared to Enpp1+/+; no effects of Enpp1 knockout on the formation or resorptive activity of osteoclasts were noted. Sclerostin, an osteocyte-derived inhibitor of WNT signalling and bone formation, was found to increase Enpp1 mRNA expression and NPP activity of osteoblasts, without affecting ALP in vitro. These results emphasise the importance of ATP and its breakdown product pyrophosphate in regulating mineralisation. 3 Acknowledgments Acknowledgments I would like to thank Prof Tim Arnett and Dr Isabel Orriss for giving me the opportunity, and allowing me the privilege, to undertake my PhD under their supervision. Both have given me more that I could ever repay and share a part in any successes I have from this day forwards. I would also like to thank Prof Alan Boyde from QMUL for performing some of the electron microscopy in this thesis and offering sage words of advice, and Dr Chris Scotton from Exeter University for assisting me in the practical aspects of histology. Finally, I would like to thank my wife Rachel. 4 Contents Contents Declaration of authorship.......................................................................... 2 Abstract........................................................................................................... 3 Acknowledgments........................................................................................ 4 Contents.......................................................................................................... 5 Figures and tables......................................................................................... 10 Chapter 1......................................................................................................... 14 Introduction............................................................................................... 14 Development of the skeleton........................................................... 14 Endochondral ossification.................................................................... 14 Intramembranous ossification............................................................. 15 Bone cells............................................................................................... 15 Osteoblasts........................................................................................... 15 Osteocytes............................................................................................ 18 Osteoclasts........................................................................................... 22 Bone matrix........................................................................................... 27 The mineralisation of bone matrix…................................................ 28 Ecto-nucleotide pyrophosphatase / phosphodiesterase1.................... 28 Alkaline phosphatase........................................................................... 29 Phospho1………………………………………………………………............................. 30 Phosphate / pyrophosphate ratio........................................................ 31 ANK transport protein.......................................................................... 33 Factors that regulate bone cells and bone formation................. 33 The vascular system………………………………………………………………………….. 33 Contents Hydrogen ions...................................................................................... 34 Glucocorticoids..................................................................................... 36 Endocrine and paracrine regulation regulators of bone cells... 36 Bone morphogenetic protein signalling............................................... 36 Vitamin D.............................................................................................. 37 Parathyroid hormone (PTH)................................................................. 38 WNT signalling...................................................................................... 39 Extracellular nucleotide signalling............................................ 43 Purinoceptor signalling and osteoblasts.............................................. 44 Purinoceptor signalling and osteoclasts............................................... 46 Ecto-nucleotidases…................................................................. 48 Ecto-nucleoside triphosphate diphosphohydrolase............................. 48 Ecto-nucleotide pyrophosphatase/phosphodiesterase....................... 49 Ecto-5’nucleotidase.............................................................................. 54 Alkaline phosphatase........................................................................... 56 Nucleoside mono/di/tri-phosphate inter-conversion................. 57 Adenosine kinase................................................................................. 58 Adenylate kinase.................................................................................. 58 Nucleoside diphosphate kinase............................................................ 59 Adenosine triphosphate synthase........................................................ 60 Adenosine and adenosine receptors............................................... 61 Adenosine deaminase.......................................................................... 64 Adenine and adenine receptors........................................................... 65 Purine salvage pathway....................................................................... 66 Aims......................................................................................................... 68 Contents Chapter 2......................................................................................................... 69 Materials and methods.......................................................................... 69 Reagents................................................................................................
Load more

Recommended publications
  • Annexes to the EMA Annual Report 2009
    Annual report 2009 Annexes The main body of this annual report is available on the website of the European Medicines Agency (EMA) at: http://www.ema.europa.eu/htms/general/direct/ar.htm 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2010. Reproduction is authorised provided the source is acknowledged. Contents Annex 1 Members of the Management Board..................................................... 3 Annex 2 Members of the Committee for Medicinal Products for Human Use .......... 5 Annex 3 Members of the Committee for Medicinal Products for Veterinary Use ....... 8 Annex 4 Members of the Committee on Orphan Medicinal Products .................... 10 Annex 5 Members of the Committee on Herbal Medicinal Products ..................... 12 Annex 6 Members of the Paediatric Committee................................................ 14 Annex 7 National competent authority partners ............................................... 16 Annex 8 Budget summaries 2008–2009 ......................................................... 27 Annex 9 European Medicines Agency Establishment Plan .................................. 28 Annex 10 CHMP opinions in 2009 on medicinal products for human use .............. 29 Annex 11 CVMP opinions in 2009 on medicinal products for veterinary use.......... 53 Annex 12 COMP opinions in 2009 on designation of orphan medicinal products
    [Show full text]
  • Myocardial Metabolism in Heart Failure: Purinergic Signalling and Other
    Accepted Manuscript Myocardial metbolism in heart failure: Purinergic signalling and other metabolic concepts Andreas L. Birkenfeld, Jens Jordan, Markus Dworak, Tobias Merkel, Geoffrey Burnstock PII: S0163-7258(18)30153-0 DOI: doi:10.1016/j.pharmthera.2018.08.015 Reference: JPT 7270 To appear in: Pharmacology and Therapeutics Please cite this article as: Andreas L. Birkenfeld, Jens Jordan, Markus Dworak, Tobias Merkel, Geoffrey Burnstock , Myocardial metbolism in heart failure: Purinergic signalling and other metabolic concepts. Jpt (2018), doi:10.1016/j.pharmthera.2018.08.015 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT Myocardial metbolism in heart failure: Purinergic signalling and other metabolic concepts Andreas L. Birkenfeld MD1,2,3,4, Jens Jordan MD5, Markus Dworak PhD6, Tobias Merkel PhD6 and Geoffrey Burnstock PhD7,8. Affiliations 1Medical Clinic III, Universitätsklinikum "Carl Gustav Carus", Technische Universität Dresden, Dresden, Germany 2Paul Langerhans Institute Dresden of the Helmholtz Center Munich at University Hospital and Faculty of Medicine, Dresden, German Center for Diabetes Research
    [Show full text]
  • Effects of Dentine Matrix Extracts on Phenotype and Behaviour of Dental Pulp Progenitor Cells
    The Effect of Dentine Conditioning Agents on Solubilisation of Bioactive Dentine Matrix Components and Dentine Regeneration A thesis submitted in fulfilment of the requirements of the degree of Doctor of Philosophy Cardiff University October 2015 Leili Sadaghiani Oral and Biomedical Sciences, School of Dentistry, College of Biomedical and Life Sciences, Cardiff University I II Acknowledgements At the start I would like to express my sincere appreciation to my supervisors, Prof. Alastair Sloan and Prof. Christopher Lynch for providing insight, guidance and encouragement throughout this work. As well as lending excellent support, they allowed me intellectual freedom in this project which enabled me grow as a scientist and I am very grateful for that. I would also like to thank Prof. Rachel Waddington for her valuable guidance during the project work. I also take this opportunity to express my gratitude to all members of the Mineralised Tissue Group, including the academic, technical and postdoctoral staff as well as postgraduate students. They provided immense support to this work by sharing their knowledge, expertise and above all friendship. The groups has to be congratulated for being such an efficient, cohesive and happy team. It has been a real joy and my pleasure to work with each and every member within it. Finally, I would like to thank my beloved family; my husband Saeed and my sons Soroush and Sepehr. I would not have been able to complete this journey without their love, understanding and support. I must also thank my parents for encouraging me in all of my pursuits in life. I would not be the person I am without them.
    [Show full text]
  • Innate Mechanisms of Antimicrobial Defense Associated with the Avian Eggshell Megan Rose-Martel
    Innate Mechanisms of Antimicrobial Defense Associated with the Avian Eggshell Megan Rose-Martel Thesis submitted to the Faculty of Graduate and Postdoctoral Studies in partial fulfillment of the requirements for the Doctorate in Philosophy degree in Cellular and Molecular Medicine Department of Cellular and Molecular Medicine Faculty of Medicine University of Ottawa © Megan Rose-Martel, Ottawa, Canada, 2015 Dedication This thesis is dedicated to the loving memory of my father. He was a man in constant pursuit of knowledge. I was constantly reminded of how proud he was of my accomplishments, both personal and scientific. He read every article I published, every poster I created and inquired constantly about the research I was conducting, wanting to know every detail. His unwavering support and encouragement was invaluable to the completion of this thesis. I am extremely saddened that he is not here with us to see the completion of this chapter of my life which would have never been possible without him. I also dedicate this thesis to my loving husband, my wonderful mother and my darling daughter for their endless love, patience and support that they show towards me every day of my life. They have helped me through the most difficult times by listening to me, making me laugh and always having faith that I could make it. They are and will always be a constant source of comfort, love and happiness. ii Acknowledgments I would like to express my sincere gratitude to my supervisor and mentor, Dr. Maxwell Hincke, for the opportunity to work in his laboratory. His encouragement, guidance and motivation throughout my Ph.D.
    [Show full text]
  • 2598 Biomineralization of Bone: a Fresh View of the Roles of Non-Collagen
    [Frontiers in Bioscience 16, 2598-2621, June 1, 2011] Biomineralization of bone: a fresh view of the roles of non-collagenous proteins Jeffrey Paul Gorski1 1Center of Excellence in the Study of Musculoskeletal and Dental Tissues and Dept. of Oral Biology, Sch. Of Dentistry, Univ. of Missouri-Kansas City, Kansas City, MO 64108 TABLE OF CONTENTS 1. Abstract 2. Introduction 3. Proposed mechanisms of mineral nucleation in bone 3.1. Biomineralization Foci 3.2. Calcospherulites 3.3. Matrix vesicles 4. The role of individual non-collagenous proteins 4.1. Bone Sialoprotein 4.2. Noggin 4.3. Chordin 4.4. Osteopontin 4.5. Osteopontin, bone sialoprotein, and DMP1 form individual complexes with MMPs 4.6. Bone acidic glycoprotein-75 4.7. Dentin matrix protein1 4.8. Osteocalcin 4.9. Fetuin (alpha2HS-glycoprotein) 4.10. Periostin 4.11. Tissue nonspecific alkaline phosphatase 4.12. Phospho 1 phosphatase 4.13. Ectonucleotide pyrophosphatase/phosphodiesterase 4.14. Biological effects of hydroxyapatite on bone matrix proteins 4.15. Sclerostin 4.16. Tenascin C 4.17. Phosphate-regulating neutral endopeptidase (PHEX) 4.18. Matrix extracellular phosphoglycoprotein (MEPE, OF45) 4.19. Functional importance of proteolysis in activation of transglutaminase and PCOLCE 4.20. Neutral proteases in bone 5. Summary and Perspective 6. Acknowledgements 7. References 1. ABSTRACT The impact of genetics has dramatically affected nteractions which act in positive and negative ways to our understanding of the functions of non-collagenous regulate the process of bone mineralization. Several new proteins. Specifically, mutations and knockouts have examples from the author’s laboratory are provided defined their cellular spectrum of actions.
    [Show full text]
  • Dentine Sialophosphoprotein Signal in Dentineogenesis and Dentine Regeneration M.M
    EuropeanMM Liu et Cells al. and Materials Vol. 42 2021 (pages 43-62) DOI: 10.22203/eCM.v042a04 DSPP signalling in dentine ISSN formation 1473-2262 DENTINE SIALOPHOSPHOPROTEIN SIGNAL IN DENTINEOGENESIS AND DENTINE REGENERATION M.M. Liu1,2, W.T. Li1,3, X.M. Xia1,4, F. Wang5, M. MacDougall6 and S. Chen1 1 Department of Developmental Dentistry, School of Dentistry, the University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA 2 Department of Endodontics, School of Stomatology, Tongji University, Shanghai, 200072, China 3 Department of Pathology, Weifang Medical University, Weifang, 261053, China 4 Department of Obstetrics and Gynaecology, Second Xiangya Hospital, Central South University Changsha, 410011, China 5 Department of Anatomy, Fujian Medical University, Fuzhou, 350122, China 6 UBC Faculty of Dentistry, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada Abstract Dentineogenesis starts on odontoblasts, which synthesise and secrete non-collagenous proteins (NCPs) and collagen. When dentine is injured, dental pulp progenitors/mesenchymal stem cells (MSCs) can migrate to the injured area, differentiate into odontoblasts and facilitate formation of reactionary dentine. Dental pulp progenitor cell/MSC differentiation is controlled at given niches. Among dental NCPs, dentine sialophosphoprotein (DSPP) is a member of the small integrin-binding ligand N-linked glycoprotein (SIBLING) family, whose members share common biochemical characteristics such as an Arg-Gly-Asp (RGD) motif. DSPP expression is cell- and tissue-specific and highly seen in odontoblasts and dentine. DSPP mutations cause hereditary dentine diseases. DSPP is catalysed into dentine glycoprotein (DGP)/sialoprotein (DSP) and phosphoprotein (DPP) by proteolysis. DSP is further processed towards active molecules.
    [Show full text]
  • Adenosine A1 Receptor Antagonists in Clinical Research and Development Berthold Hocher1,2
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector mini review http://www.kidney-international.org & 2010 International Society of Nephrology Adenosine A1 receptor antagonists in clinical research and development Berthold Hocher1,2 1Institute of Nutritional Science, University of Potsdam, Potsdam, Germany and 2Center for Cardiovascular Research/Department of Pharmacology and Toxicology, Charite´, Campus Mitte, Berlin, Germany Selective adenosine A1 receptor antagonists targeting renal Various lines of evidence implicate impaired renal function as microcirculation are novel pharmacologic agents that are a risk factor in patients with congestive heart failure (CHF). currently under development for the treatment of acute Conventional diuretics may aggravate renal dysfunction and heart failure as well as for chronic heart failure. Despite can result in neurohumoral activation and activation of the several studies showing improvement of renal function TGF mechanism in the kidney.1 Impaired kidney function and/or increased diuresis with adenosine A1 antagonists, might not just be a risk factor, but is also currently observed particularly in chronic heart failure, these findings were as having a role—and thus potentially as target—in disease not confirmed in a large phase III trial in acute heart failure progression of heart failure patients.1 Evolving new ther- patients. However, lessons can be learned from these and apeutic strategies that enhance renal function include other studies, and there might still be a potential role for administration of B-type natriuretic peptide, adenosine the clinical use of adenosine A1 antagonists. and vasopressin antagonists, and ultrafiltration methods. We review the role of adenosine A1 receptors in the Prospective studies are needed to evaluate whether these new regulation of renal function, and emerging data regarding renal-enhancing strategies will improve patient outcome in the safety and efficacy of A1 adenosine receptor antagonists CHF.
    [Show full text]
  • Illinois College Jacksonville, Illinois
    TRANSACTIONS OF THE ILLINOIS STATE ACADEMY OF SCIENCE Supplement to Volume 106 105th Annual Meeting April 5-6, 2013 Illinois College Jacksonville, Illinois Illinois State Academy of Science Founded 1907 Affiliated with the Illinois State Museum, Springfield, Illinois TABLE OF CONTENTS Schedule of Events 3 Presentation Schedules At-a-Glance 4 ORAL AND POSTER PRESENTATION SESSIONS Oral Presentation Sessions: Title and Author Listings Session 1: Physics, Mathematics, & Astronomy 5 Session 2: Botany 5 Session 3: Cell, Molecular, & Developmental Biology 7 Session 4: Chemistry & Computer Science 8 Session 5: Environmental Science/Zoology 9 Session 6: Health Sciences, Microbiology, and STEM Education 10 Session 7: Zoology 11 Poster Presentation Sessions: Title and Author Listings Agriculture 13 Botany 13 Cell, Molecular, & Developmental Biology 15 Chemistry 16 Computer Science 17 Earth Science 18 Environmental Science 18 Health Sciences 19 Microbiology 19 Physics, Mathematics, & Astronomy 20 Zoology 21 1 ORAL AND POSTER PRESENTATION ABSTRACTS Oral Presentation Abstracts Session 1: Physics, Mathematics, & Astronomy 24 Session 2: Botany 25 Session 3: Cell, Molecular, & Developmental Biology 30 Session 4: Chemistry & Computer Science 35 Session 5: Environmental Science/Zoology 38 Session 6: Health Sciences, Microbiology, and STEM 42 Session 7: Zoology 45 Poster Presentation Abstracts Agriculture 50 Botany 50 Cell, Molecular, & Developmental Biology 59 Chemistry 66 Computer Science 70 Earth Science 71 Environmental Science 72 Health Sciences 74 Microbiology
    [Show full text]
  • Heart Failure Guidelines
    ; ; ; † § ** ; ; † † * ; ; † † ; ; ¶ † ; * † * ; . 2013;128:e240–e327. † ; DOI: 10.1161/CIR.0b013e31829e8776 †‡ Circulation * †† * ; Tamara Horwich, MD, FACC Tamara ; ‖ ; Barbara Riegel, DNSc, RN, FAHA ; Barbara Riegel, ; Patrick E. McBride, MD, MPH, FACC ; Patrick † ; Wayne C. Levy, MD, FACC C. Levy, Wayne ; # † † ; Emily J. Tsai, MD, FACC ; Emily J. ; Biykem Bozkurt, MD, PhD, FACC, FAHA Bozkurt, MD, PhD, FACC, ; Biykem ; Gregg C. Fonarow, MD, FACC, FAHA MD, FACC, C. Fonarow, ; Gregg † † † * * * e240 ; Lynne W. Stevenson, MD, FACC Stevenson, W. ; Lynne ; Judith E. Mitchell, MD, FACC, FAHA ; Judith E. Mitchell, MD, FACC, † † ; Maryl R. Johnson, MD, FACC, FAHA ; Maryl R. Johnson, MD, FACC, * † * ; Donald E. Casey, Jr, MD, MPH, MBA, FACP, FAHA FACP, MD, MPH, MBA, Jr, ; Donald E. Casey, † * WRITING COMMITTEE MEMBERS Bruce L. Wilkoff, MD, FACC, FHRS MD, FACC, Wilkoff, Bruce L. Journal of the American College of Cardiology. American College of the Journal Management of Heart Failure Clyde W. Yancy, MD, MSc, FACC, FAHA, Chair FAHA, MD, MSc, FACC, Yancy, W. Clyde ACCF/AHA Practice Guideline ACCF/AHA International Society for Heart and Lung Transplantation International Society for Heart and Lung 2013 ACCF/AHA Guideline for the Guideline for ACCF/AHA 2013 W.H. Wilson Tang, MD, FACC Tang, Wilson W.H. Flora Sam, MD, FACC, FAHA Flora Sam, MD, FACC, Heart Association Task Force on Practice Guidelines Force Task Association Heart Edward K. Kasper, MD, FACC, FAHA MD, FACC, K. Kasper, Edward James L. Januzzi, MD, FACC John J.V. McMurray, MD, FACC McMurray, John J.V. Stephen A. Geraci, MD, FACC, FAHA, FCCP FAHA, A. Geraci, MD, FACC, Stephen . 2013;128:e240-e327.) is available at http://circ.ahajournals.org is available Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation Association of Cardiovascular American by the Endorsed Pamela N.
    [Show full text]
  • Deciphering the Relevance of Bone ECM Signaling
    cells Review Deciphering the Relevance of Bone ECM Signaling Natividad Alcorta-Sevillano y, Iratxe Macías y, Arantza Infante * and Clara I. Rodríguez * Stem Cells and Cell Therapy Laboratory, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Plaza de Cruces S/N, Barakaldo, 48903 Bizkaia, Spain; [email protected] (N.A.-S.); [email protected] (I.M.) * Correspondence: [email protected] (A.I.); [email protected] (C.I.R.) These authors contributed equally. y Received: 20 October 2020; Accepted: 7 December 2020; Published: 7 December 2020 Abstract: Bone mineral density, a bone matrix parameter frequently used to predict fracture risk, is not the only one to affect bone fragility. Other factors, including the extracellular matrix (ECM) composition and microarchitecture, are of paramount relevance in this process. The bone ECM is a noncellular three-dimensional structure secreted by cells into the extracellular space, which comprises inorganic and organic compounds. The main inorganic components of the ECM are calcium-deficient apatite and trace elements, while the organic ECM consists of collagen type I and noncollagenous proteins. Bone ECM dynamically interacts with osteoblasts and osteoclasts to regulate the formation of new bone during regeneration. Thus, the composition and structure of inorganic and organic bone matrix may directly affect bone quality. Moreover, proteins that compose ECM, beyond their structural role have other crucial biological functions, thanks to their ability to bind multiple interacting partners like other ECM proteins, growth factors, signal receptors and adhesion molecules. Thus, ECM proteins provide a complex network of biochemical and physiological signals. Herein, we summarize different ECM factors that are essential to bone strength besides, discussing how these parameters are altered in pathological conditions related with bone fragility.
    [Show full text]
  • WO 2011/089216 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date t 28 July 2011 (28.07.2011) WO 2011/089216 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 47/48 (2006.01) C07K 1/13 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 1/1 07 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) Number: International Application DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/050821 HN, HR, HU, ID, J , IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 2 1 January 201 1 (21 .01 .201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1015 1465. 1 22 January 2010 (22.01 .2010) EP kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): AS- ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, CENDIS PHARMA AS [DK/DK]; Tuborg Boulevard TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 12, DK-2900 Hellerup (DK).
    [Show full text]
  • MK-7418 Prot. No. 301-302 PROTECT 2. Synopsis
    MK-7418 Prot. No. 301-302 PROTECT 2. Synopsis MERCK RESEARCH CLINICAL STUDY REPORT LABORATORIES SYNOPSIS MK-7418 rolofylline, IV Congestive Heart Failure PROTOCOL TITLE/NO.: A Multicenter, Randomized, Double-Blind, Placebo- #301-302 Controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms and Renal Function in Subjects with Acute Heart Failure Syndrome and Renal Impairment who are Hospitalized for Volume Overload and Require Intravenous Diuretic Therapy. PROTECTION OF HUMAN SUBJECTS: This study was conducted in conformance with applicable country or local requirements regarding ethical committee review, informed consent, and other statutes or regulations regarding the protection of the rights and welfare of human subjects participating in biomedical research. For study audit information see [16.1.8]. INVESTIGATOR(S)/STUDY CENTER(S): Multicenter 239 sites Worldwide, 18 countries [16.1.3.1; 16.1.4.1] PUBLICATION(S): PRIMARY THERAPY PERIOD: 02May2007 to 23JAN2009. CLINICAL III Day 60 Follow-Up completed 23MAR2009; Day 180 Follow-up PHASE: completed 30JUL2009. DURATION OF TREATMENT: All patients were treated with active drug or exact match placebo given as a 4-hour intravenous infusion for up to 3 days or until discharge, whichever occurred first. OBJECTIVE(S): The objectives of this study were to evaluate the effect of rolofylline in addition to intravenous (IV) loop diuretic therapy on heart failure signs and symptoms, persistent renal dysfunction, morbidity and mortality, and safety in subjects hospitalized with acute heart failure syndrome (AHFS), volume overload, and renal impairment, and to estimate and compare within-trial medical resource utilization and direct medical costs between patients treated with rolofylline and placebo.
    [Show full text]